Board of Directors

Dr. Lance Willsey was appointed Interim Chairman of the Board on September 30, 2024. He was appointed member of the Board of Directors in December 2023. Dr. Lance Willsey, M.S., M.D. is a urologist who has an aggregate of 36 years of private and public board experience focused in the area of cancer diagnostics and therapeutics. He completed his surgical and urology training at the Massachusetts General Hospital and additional postgraduate training in the Steele Lab Harvard University and the Dana Farber Cancer Institute. Lance is a founding Partner of Healthcare fund DCF Capital. He also actively participated in boards as a Director of Exact Sciences from 1999 to 2009 and of Exelixis from 1997 to 2023. Lance helped guide the two companies through their IPO process as well as subsequent financings. He also has extensive experience in corporate governance having served on audit, compensation, finance and scientific advisory committees.

Ryan Rhodes was appointed as a member of the Board of Directors in August 2023. Ryan was appointed Chief Executive Officer of Company on May 1, 2023, to lead, strengthen and accelerate the Company’s corporate strategy and development. Mr. Rhodes is a passionate executive with over 30 years of leadership experience in market development in the medical device industry, including 20 years dedicated to medical robotics. Prior to joining EDAP, Ryan served as the CEO of Restoration Robotics, the global leader in robotic aesthetic medicine where he led the company to a successful merger with Venus Concept Inc. in 2019. Prior to Restoration Robotics, Ryan spent over 13 years at Intuitive Surgical, the global leader in medical robotics where he was a key architect of the company’s multi-procedure market focus and development efforts, including the successful launch of the global Urology franchise. Prior to Intuitive Surgical, he spent over 11 years in various management positions in sales, marketing, professional education, and market development at Ethicon Inc., a Johnson & Johnson Company. Ryan holds a B.A in Public Administration from San Diego State University.

Fran Schulz joined the Company’s Board of Directors in June 2024. Ms. Schulz is a seasoned executive with over 35 years of experience with EY who has spent her career working with large public and emerging private companies in the life sciences industry. Ms. Schulz also has significant experience working on U.S. Securities and Exchange Commission (“SEC”) and International Financial Reporting Standards (“IFRS”) matters. She is qualified to serve as a financial expert under SEC, NYSE and NASDAQ rules. Ms. Schulz currently also serves as a Board Member of Senti Biosciences and Menlo College . Previously, she served as a Board Member for the National board of Women in Bio (2013 – 2023) and for the California Life Sciences Industry Association. Ms. Schulz is a licensed certified public accountant (CPA) licensed in California. Ms. Schulz received her B.S. in Business Administration from Menlo College.

M. Levine was appointed as a member of the Board of Directors in January 2025. Mr. Levine is a strategic business leader with decades of diverse global board and executive management experience within the medical technology industry. He possesses a deep expertise in portfolio transformation, strategic business development and driving shareholder value. From 2012 to 2022, Mr. Levine served as President, Chief Executive Officer, and Director of Accuray Incorporated, where he led a transformative turnaround that involved all strategic, operational, and financial activities that restored the business to consistent top line growth, positive operating profit, free cash flow (EBITDA), and expanded the company’s global footprint. Before joining Accuray, Mr. Levine served as President, Chief Executive Officer, and Board Member of Immucor, Inc. (Nasdaq: BLUD), where he led the transition from the company being publicly traded up until its acquisition as a private entity by TPG Capital in August 2011 for approximately $2 billion. From 2004 to 2010, Mr. Levine served as President, Chief Executive Officer and Board Member of Mentor Corporation (NYSE: MNT), where he played an instrumental role in repositioning the company by executing a strategic transformation focused on higher growth markets, ultimately leading to the company’s acquisition by Johnson & Johnson (J&J) in June 2008 for $1.2 billion. Mr. Levine has completed executive management programs at UCLA Anderson School of Business, Stanford University, and University of Pennsylvania, and he received his bachelor’s degree in communications from the University of Arizona.

David R. Horn was appointed as a member of the Company’s Board of Directors in February 2026. He has served as President and Chief Financial Officer of Seer, Inc. since 2023, having originally joined the company as Chief Financial Officer in 2020. In his roles at Seer, David oversees the company’s finance and operational functions and works closely with the board and management team on strategic planning, capital markets execution, and long-term value creation. Prior to joining Seer, David spent more than 20 years at Morgan Stanley, where he served as a Managing Director in the Healthcare Investment Banking Group. During his tenure, he led Morgan Stanley’s global Life Science Tools and Diagnostics practice and oversaw the firm’s Western Region Healthcare practice, advising public and private healthcare companies on capital markets transactions, mergers and acquisitions, and strategic initiatives. Earlier in his career, David worked in the medical device and life sciences sectors, serving as Vice President of Business Development at RITA Medical Systems and previously in the same role at Chemdex Corporation. David holds an A.B. from Princeton University and an M.B.A. from the Stanford University Graduate School of Business.